Skip to main content

Table 1 Patients characteristics and survival

From: Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

  N (%) Median OS   Median PFS  
    months logrank months logrank
Age   47 (15–84)     
  <=60 145 (80) 16.9 0.05 3.3 0,13
  >60 36 (20) 11.7   3.0  
Male   83 (46) 14,7 0.36 3.8 0,78
Female   98 (54) 16,6   3.1  
Site
  Inf limb 59 (33) 17.1 0.15 4.8 0.03
  Sup Limb 12 (7) 16.6   2.3  
  Retroperitoneum 33 (18) 19.6   9.1  
  Uterus 24 (13) 13.9   3.0  
  Other trunk 45 (25) 9.3   2.7  
  Head/Neck 8 (4) 17.0   4.0  
Histotypes
  LMS 55 (30) 17,4 0.005 3.4 0.005
  Myxoid LPS 28 (16) 33.4   10,5  
  LPS (other) 21 (11) 20.0   3.2  
  NOS/undiff. 22 (12) 14,0   2.2  
  Synovial 16 (9) 9.2   4.0  
  Others/Misc 39 (22) 6.7   2.1  
Myxoid LPS
  Yes 28 (15) 33.4 0.01 10,5 0.000
  No 153 (85) 13.9   2.8  
Translocation sarcomas
  Yes 54 (30) 15.3 0.17 5.3 0,02
  No 119 (66) 14.7   2.8  
Grade
  1 17 (9) 16.9 0.43 9.7 0,17
  2 51 (28) 18.6   4.4  
  3 80 (44) 16.0   3.6  
  UNK 33 (19) 10.7   2.8  
Treatment line for ET-743 (median: 3, range 1–4)
  1* 10 (6) 33.4 0.03 4.5 0.04
  2 67 (37) 18.2   5.3  
  3 60 (33) 14.3   3.2  
  4 42 (23) 10.2   2.8  
* doxorubicin and ifosfamide in the adjuvant setting
Hospitalisation for toxicity (reported in N = 152)
  Yes 30 (17) 6.7 0.03 2.5 0.39
  No 122 (65) 18.2   4.5  
Lung metastases
  Yes 128 (71) 14.7 0.93 3.0 0.054
  No 47 (25) 16.9   6.7  
Liver metastases
  Yes 45 (25) 16.8 0.51 3.0 0.83
  No 125 (70) 13.5   3.6